HSBC Holdings
KPTI icon

HSBC Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

HSBC Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137K Buy
13,750
+2,255
+20% +$19.6K ﹤0.01% 2766
2026
Q1 		$65.6K Buy
+11,495
New +$87.6K ﹤0.01% 2787
2025
Q1 		– Sell
-2,687
Closed -$26.5K – 3166
2024
Q4 		$26.5K Hold
2,687
– – ﹤0.01% 3042
2024
Q3 		$31K Sell
2,687
-852
-24% -$10.6K ﹤0.01% 2918
2024
Q2 		$48.1K Sell
3,539
-32
-0.9% -$530 ﹤0.01% 2822
2024
Q1 		$80.9K Buy
3,571
+552
+18% +$9.68K ﹤0.01% 2878
2023
Q4 		$38.9K Buy
3,019
+24
+0.8% +$323 ﹤0.01% 2661
2023
Q3 		$60.4K Buy
2,995
+2,176
+266% +$48.8K ﹤0.01% 2610
2023
Q2 		$22.3K Hold
819
– – ﹤0.01% 2519
2023
Q1 		$46.8K Buy
+819
New +$40.4K ﹤0.01% 2570
2021
Q2 		– Sell
-949
Closed -$149K – 3007
2021
Q1 		$149K Sell
949
-486
-34% -$102K ﹤0.01% 2591
2020
Q4 		$330K Buy
1,435
+155
+12% +$35.9K ﹤0.01% 2503
2020
Q3 		$283K Buy
1,280
+34
+3% +$8.32K ﹤0.01% 2287
2020
Q2 		$354K Buy
1,246
+353
+40% +$104K ﹤0.01% 2038
2020
Q1 		$252K Buy
+893
New +$246K ﹤0.01% 2158

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's KPTI Position: Q2 2026 in Review

HSBC Holdings increased its Karyopharm Therapeutics (KPTI) stake by 20% in Q2 2026, buying an estimated $19.6K and bringing the position to 13,750 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #2766.

HSBC Holdings first reported a position in KPTI in Q1 2020 and has held it in 15 quarters since. The position peaked at $354K in Q2 2020. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • HSBC Holdings held 13,750 shares of Karyopharm Therapeutics worth $137K as of Q2 2026.
  • HSBC Holdings bought 2,255 Karyopharm Therapeutics shares in Q2 2026, an estimated $19.6K.
  • Karyopharm Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2766 holding.
  • HSBC Holdings first reported a position in Karyopharm Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • HSBC Holdings's Karyopharm Therapeutics position peaked at $354K in Q2 2020.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.